Production (Stage)
Avidity Biosciences, Inc.
RNA
$30.58
-$0.23-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.57M | 2.97M | 2.34M | 2.05M | 3.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.57M | 2.97M | 2.34M | 2.05M | 3.54M |
| Cost of Revenue | 99.49M | 95.63M | 77.20M | 63.94M | 66.83M |
| Gross Profit | -97.92M | -92.65M | -74.86M | -61.90M | -63.29M |
| SG&A Expenses | 33.60M | 28.34M | 23.27M | 20.73M | 13.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.09M | 123.96M | 100.47M | 84.67M | 80.73M |
| Operating Income | -131.52M | -120.99M | -98.13M | -82.63M | -77.19M |
| Income Before Tax | -115.77M | -102.26M | -80.40M | -70.79M | -68.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -115.77M | -102.26M | -80.40M | -70.79M | -68.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -115.77M | -102.26M | -80.40M | -70.79M | -68.86M |
| EBIT | -131.52M | -120.99M | -98.13M | -82.63M | -77.19M |
| EBITDA | -130.73M | -120.25M | -97.42M | -81.94M | -76.55M |
| EPS Basic | -0.90 | -0.80 | -0.65 | -0.66 | -0.79 |
| Normalized Basic EPS | -0.56 | -0.50 | -0.41 | -0.41 | -0.49 |
| EPS Diluted | -0.90 | -0.80 | -0.65 | -0.66 | -0.79 |
| Normalized Diluted EPS | -0.56 | -0.50 | -0.41 | -0.41 | -0.49 |
| Average Basic Shares Outstanding | 129.23M | 128.50M | 123.38M | 106.93M | 87.21M |
| Average Diluted Shares Outstanding | 129.23M | 128.50M | 123.38M | 106.93M | 87.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |